MPPE1 and neoplasm: Therefore, identifying barriers and facilitators of cDC1 reprogramming and the development of spheroid-based platforms to predict the efficacy of tumour-APC-based immunotherapy may facilitate the selection of patients who will benefit the most from this therapy.